Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 620 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buprenorphine Clear all
Completed Phase 2 Interventional Results available

Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder

NCT02044094
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine, buprenorphine and naloxone, hydromorphone, placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 20, 2026, 6:00 AM EDT
Completed Not applicable Interventional

Mindful Body Awareness With Medication Treatment for Opioid Use Disorder

NCT04082637
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Mindful Awareness in Body-oriented Therapy
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Bellingham, Washington • Port Angeles, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 20, 2026, 6:00 AM EDT
Completed Phase 2 Interventional

Buprenorphine Pharmacology Related to Addiction Treatment - 21

NCT00000239
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 17, 2005 · Synced Oct 20, 2026, 6:00 AM EDT
Completed Phase 1Phase 2 Interventional

CBT4CBT for Office Based Buprenorphine

NCT03580902
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
CBT4CBT-Buprenorphine, Buprenorphine/naloxone
Behavioral · Drug
Lead sponsor
CBT4CBT, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 20, 2026, 6:00 AM EDT
Completed Not applicable Interventional

Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support

NCT04309565
View directory record Official record
Conditions
Opioid Addiction
Interventions
Transitions Clinic Network Primary Care, Standard Primary Care
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
New Haven, Connecticut • Minneapolis, Minnesota • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 20, 2026, 6:00 AM EDT
Completed Phase 4 Interventional

Integrating Buprenorphine Into the SFGH AIDS Program

NCT00263458
View directory record Official record
Conditions
HIV, Buprenorphine, Opioid Dependence
Interventions
Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
19 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 20, 2026, 6:00 AM EDT
Completed Phase 2 Interventional Results available

A Multiple Dose Opioid Challenge Study

NCT02611752
View directory record Official record
Conditions
Moderate or Severe Opioid Use Disorder
Interventions
CAM2038
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Overland Park, Kansas • Lexington, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 20, 2026, 6:00 AM EDT
Completed Phase 2 Interventional Results available

Buprenorphine for Late-Life Treatment Resistant Depression

NCT01071538
View directory record Official record
Conditions
Depression
Interventions
Buprenorphine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 20, 2026, 6:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole

NCT01259115
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine transdermal patch, Ketoconazole tablet, Placebo to match ketoconazole tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 54 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 20, 2026, 6:00 AM EDT
Completed No phase listed Observational

Treatment Study: Reducing Cocaine/Heroin Abuse With SR-Amphetamine and Buprenorphine (ARC)

NCT00698737
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders, Cocaine Abuse or Dependence
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 22, 2012 · Synced Oct 20, 2026, 6:00 AM EDT
Completed Not applicable Interventional

The Whole Health Study: Collaborative Care for OUD and Mental Health Conditions

NCT04245423
View directory record Official record
Conditions
Opioid-use Disorder, Mental Health Conditions
Interventions
Collaborative Care for Opioid Use Disorders and Mental Health Conditions, Augmented Usual Care, Collaborative Care for Opioid Use Disorders and Mental Health Conditions Plus Certified Recovery Specialists
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 20, 2026, 6:00 AM EDT
Recruiting Not applicable Interventional

Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents

NCT06732596
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Embodied conversational agent (ECA), Technical support, Additional ECA messages, Additional incentives
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 20, 2026, 6:00 AM EDT
Completed Phase 2 Interventional

Buprenorphine Detoxification - BBDVI - 19

NCT00000237
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 17, 2005 · Synced Oct 20, 2026, 6:00 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Combined Injectable Treatment for HIV and OUD

NCT05991622
View directory record Official record
Conditions
Human Immunodeficiency Virus, Opioid Use Disorder
Interventions
Combined LAI Treatment: Cabenuva and Sublocade
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 20, 2026, 6:00 AM EDT
Completed Phase 2 Interventional Results available

Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals

NCT01262092
View directory record Official record
Conditions
Opioid Dependence, Opioid Withdrawal, Opioid Detoxification
Interventions
Buprenorphine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 20, 2026, 6:00 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Naive Subjects

NCT01633944
View directory record Official record
Conditions
Low Back Pain
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
60
States / cities
Mobile, Alabama • Phoenix, Arizona • Anaheim, California + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 20, 2026, 6:00 AM EDT
Completed Not applicable Interventional Results available

Reward-Based Recovery Outcomes Management for Opioid Use Disorder

NCT04669249
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
PROCare
Behavioral
Lead sponsor
Medical Decision Logic, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 20, 2026, 6:00 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Efficacy of Buprenorphine on Postoperative Endodontic Analgesia

NCT03268278
View directory record Official record
Conditions
Postoperative Pain
Interventions
Buprenorphine, Sterile saline, lidocaine, epinephrine (Local anesthetic)
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 20, 2026, 6:00 AM EDT
Completed Phase 1 Interventional

Reducing Drug Use and HIV Risk in Drug-dependent Adults Arrested for Prostitution

NCT01560221
View directory record Official record
Conditions
Substance-related Disorders, HIV Risk Behavior
Interventions
Therapeutic Workplace, Methadone, Buprenorphine
Behavioral · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 20, 2026, 6:00 AM EDT
Not yet recruiting Not applicable Interventional

Improving Access to Opioid Use Disorder Treatment Among Marginalized Patients With a Tailored Telehealth Intervention

NCT06341608
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Telehealth for opioid use disorder treatment delivery
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 20, 2026, 6:00 AM EDT
Completed Phase 2 Interventional

Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)

NCT01708707
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Withdrawal Syndrome
Interventions
Buprenorphine, Morphine Sulfate
Drug
Lead sponsor
Pediatrix
Other
Eligibility
Up to 1 Year
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 20, 2026, 6:00 AM EDT
Completed Phase 4 Interventional Results available

Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

NCT04995029
View directory record Official record
Conditions
Moderate to Severe Opioid-use Disorder
Interventions
Transmucosal Buprenorphine, Extended-release Buprenorphine
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
785 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
28
States / cities
Garden Grove, California • Panorama City, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 20, 2026, 6:00 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II)

NCT00929253
View directory record Official record
Conditions
Opiate Addiction
Interventions
Suboxone, CRA, Therapy, CM
Drug · Behavioral
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 20, 2026, 6:00 AM EDT
Completed Phase 2 Interventional Results available

Buprenorphine's Dose Response Curve

NCT00460239
View directory record Official record
Conditions
Opioid-related Disorders
Interventions
Buprenorphine, Morphine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 20, 2026, 6:00 AM EDT